Cladribine plus cytarabine plus venetoclax in acute myeloid leukemia relapsed or refractory to venetoclax plus hypomethylating agent

Haematologica. 2024 Mar 28. doi: 10.3324/haematol.2024.284962. Online ahead of print.

Authors

Nickolas Steinauer¹, Kristen McCullough¹, Aref Al-Kali¹, Hassan B Alkhateeb¹, Kebede H Begna¹, Abhishek A Mangaonkar¹, Antoine N Saliba¹, Mehrdad Torghabeh¹, Mark R Litzow¹, William J Hogan¹, Mithun Shah¹, Mrinal M Patnaik¹, Animesh Pardanani¹, Talha Badar², Hemant Murthy², James Foran², Cecilia Arana Yi³, Ayalew Tefferi¹, Naseema Gangat⁴

Affiliations

¹ Division of Hematology, Mayo Clinic, Rochester, MN.
² Division of Hematology, Mayo Clinic, Jacksonville, FL.
³ Division of Hematology, Mayo Clinic, Scottsdale, AZ.
⁴ Division of Hematology, Mayo Clinic, Rochester, MN. gangat.naseema@mayo.edu.

PMID: 38546692
DOI: 10.3324/haematol.2024.284962

Abstract

Not available.